Rajesh K Malik (Rajesh Malik)

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 3

Top Topics

Chemotherapy Induced

Small Cell Lung Cancer

Brain Metastases

Top Venues

Future oncology (London, England)

Science translational medicine

Cancer chemotherapy and pharmacology

G1 Therapeutics

This page only lists publications with an associated author ORCID identifier.

Affiliation History

G1 Therapeutics

United States

Chief Medical Officer

Publications

Shom Goel, Antoinette R Tan, Hope S Rugo, Philippe Aftimos, Zoran Andrić, Andrew P Beelen, Jingshan Zhang, John S Yi, Rajesh K Malik, Joyce O'Shaughnessy
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. Future oncology (London, England) (2022)
Chao Li, Lowell Hart, Taofeek K Owonikoko, Raid Aljumaily, Caio Max Rocha Lima, Paul R Conkling, Roy Timothy Webb, Robert M Jotte, Steven Schuster, William J Edenfield, Deborah A Smith, Mark Sale, Patrick J Roberts, Rajesh K Malik, Jessica A Sorrentino
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer. Cancer chemotherapy and pharmacology 87 (5) (2021)
Shenghui He, Patrick J Roberts, Jessica A Sorrentino, John E Bisi, Hannah Storrie-White, Renger G Tiessen, Karenann M Makhuli, William A Wargin, Henko Tadema, Ewoud-Jan van Hoogdalem, Jay C Strum, Rajesh K Malik, Norman E Sharpless
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Science translational medicine 9 (387) (2018)